Progen warrants OKed for Nasdaq listing

Australia's Progen Pharmaceuticals says that its warrants, which were issued in connection with the company's recently-closed entitlements offering, have been approved for listing on the USA's Nasdaq Capital Market, and will be traded under the ticker symbol PGLAW, effective at market open on July 26.

In order to exercise rights under the warrants, investors must pay the warrant agent the exercise price equal to the US dollar equivalent of A$8.40 per share on the date of exercise, converted using the average interbank rate on the date of payment. The right to purchase shares by exercise of the warrants may be made at any time during the period expiring on May 28, 2010.